{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifn2filtkn74pjh7yvrmhgr6j7sh5hh7mlfi5bevef377agupfwhy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mgnvbv5urmp2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidtazr74d2zpmamjuaxph3nbamos4lc7c7khk6urgo6cg5nddcldm"
    },
    "mimeType": "image/jpeg",
    "size": 151605
  },
  "path": "/news/2026-03-blood-immune-fingerprint-side-effects.html",
  "publishedAt": "2026-03-09T17:20:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A team of University of Kentucky researchers has uncovered a surprising clue in the battle against Alzheimer's disease that could help doctors predict, and ultimately prevent, a common side effect of the newest generation of Alzheimer's therapies. Their findings, recently published in Nature Communications, reveal a distinct immune \"fingerprint\" in the blood of patients who develop amyloid-related imaging abnormalities (ARIA) after treatment with lecanemab—the first Food and Drug Administration-approved drug shown to slow Alzheimer's disease progression.",
  "title": "Blood immune 'fingerprint' may help predict serious side effects of new Alzheimer's drug"
}